Baxter International Inc (BAX) : Saddle Road Partners scooped up 7,100 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 15,316 shares of Baxter International Inc which is valued at $663,489.Baxter International Inc makes up approximately 0.14% of Saddle Road Partners’s portfolio.
Baxter International Inc opened for trading at $44.34 and hit $44.78 on the upside on Wednesday, eventually ending the session at $44.18, with a gain of 0.48% or 0.21 points. The heightened volatility saw the trading volume jump to 1,19,37,938 shares. Company has a market cap of $24,205 M.
Other Hedge Funds, Including , Horrell Capital Management boosted its stake in BAX in the latest quarter, The investment management firm added 218 additional shares and now holds a total of 27,000 shares of Baxter International Inc which is valued at $1,169,640. Baxter International Inc makes up approx 0.72% of Horrell Capital Management’s portfolio.First Quadrant L Pca reduced its stake in BAX by selling 18 shares or 5.42% in the most recent quarter. The Hedge Fund company now holds 314 shares of BAX which is valued at $13,602.Palisade Asset Management boosted its stake in BAX in the latest quarter, The investment management firm added 120 additional shares and now holds a total of 139,399 shares of Baxter International Inc which is valued at $5,950,943. Baxter International Inc makes up approx 1.15% of Palisade Asset Management’s portfolio.Kanaly Trust Co reduced its stake in BAX by selling 21 shares or 11.41% in the most recent quarter. The Hedge Fund company now holds 163 shares of BAX which is valued at $6,958. Banced Corp sold out all of its stake in BAX during the most recent quarter. The investment firm sold 8,044 shares of BAX which is valued $343,398.
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016. Company shares were Reiterated by RBC Capital Mkts on Feb 3, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 40 from a previous price target of $37 .
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.